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The recent decision by Judge Sweet in Association for Molecular Pathology, et al. v. U.S. 
Patent and Trademark Office, et al has the potential to dramatically alter the landscape of 
pharmaceutical research in the United States.  As more companies use genetic data and 
research to tailor drugs to specific individuals, gene patents have become a tool to insure 
long-term profitability.  While the district court’s decision will be tested on appeal, the 
industry must face the possibility that gene patents may be curtailed or even eliminated.  




Pharmaceuticals are big business in the United States. Sales of brand and generic 
drugs in the United States reached $ 274.7 billion in 2006.
1 The federal government and 
the public pay enormous amounts of money for medications, and the growing costs 
concern all levels of society.  Part of this increased cost can be directly attributed to the 
increasing costs to develop new drugs. Drug research and development (R&D) is an 
expensive process.    For drugs specifically, economists estimate that it takes twelve to 
fifteen years to develop a single new drug and have it approved by the Food and Drug 
Administration (FDA).
2 The average cost: $ 800 million.
3 The ratio of researched 
products to usable products is staggering. For every 10,000 compounds investigated, only 
five are ever tested as potential medicines in clinical trials and only one is ever approved 
for patient use. Of all the drugs approved by the FDA, only three out of ten generate 
revenues that meet or exceed average research and development costs.
4 
The investments made into the industry have borne fruit: in 2005, pharmaceutical 
companies invested almost $20 billion in R&D.
5 Since that investment, nearly 400 new 
products are either in the market or in development.
6  One of the pillars of current 
pharmaceutical research and development is gene patenting.
7  Without patent rights being 
secured, the Biotechnology Industry Organization (BIO) asserts the pharmaceutical 
development would be nearly impossible.  Naturally BIO is at best a source predisposed 
to favor pharmaceutical companies, but it does raise the question of how changes to gene 
patenting will impact drug development in the United States. 
 4 
 
As a general matter, the patent system is central to the biotechnology and 
pharmaceutical industries.  Industries that do not advance rapidly, such as those 
dependent on the expensive drug development process, rely upon the 
full patent exclusivity period to recoup the discovery and development costs.
 8 
Furthermore, pharmaceutical innovators typically able to access only about half of the 
20-year period of patent exclusivity due to the delay between needing patent protection 
and bringing the drug to the market.
9  
Drugs already being developed use the protection offered by gene patents-- 
biopharmaceutical drugs ("biologics") currently make up 40% of all preclinical 
candidates and 25% of all new drug submissions for U.S. market approval.
10 Biologics 
are usually protected by gene patents.
11  Examples of biologics on the market include 
growth factors, monoclonal antibodies, hormones, cytokines, fusion proteins, blood 
factors, recombinant enzymes, recombinant vaccines, anticoagulants, and nucleic acids.
12 
The variety of drug types is matched by the variety of diseases treated.  Biologics are 
used to treat a variety of disorders such as cancer, AIDS, influenza, hepatitis, and 
diabetes.
13  Beyond the medical impact on individual consumers, biologics have been 
successful in the marketplace. In 2006, biologics brought in over $30 billion in sales in 
the United States.
14  Biologics are expected to continue to have a significant role as drug 
therapies.
15 
With that incentive, it is unsurprising that gene patenting is extensive in the 
United States.  In 2004, Murray and Jensen published a prominent article in the journal 
Science: they reported that the USPTO had issued 4,270 human gene patents for 4,382 5 
 
distinct human genes. Based on this result, they determined that approximately one-fifth 
of known human genes were claimed in a U.S. patent.
16 Beyond human genes, there are 
approximately 20,000 patents covering a wide range of naturally occurring animal, plant, 
fungi and other DNA sequences.
17 Gene patents include “[n]ine patents [that] have been 
applied for on the genes which determine your eyeball, 40 on those for your heart, and no 
fewer than 152 on a single grain of rice.”
18   
However, scholars and practitioners often question the scope and validity of gene 
patents on the grounds that genes are so essential for any being and so important to basic 
research that it is unethical to grant a private monopoly on them. Moreover there are a 
limited number of genes found in nature- a creative researcher cannot simply invent new 
natural genes. Opponents of gene patents claim that genes should not 
be patentable subject matter because DNA sequences are at the core of humanity, which 
should not be controllable by individuals.
19 The USPTO has declined to rule on this issue, 
instead treating gene patenting as matter of statutory interpretation.
20  Therefore, attempts 
to end gene patents generally aim to overturn court precedent or to advocate new 
legislation.  
A recent decision in the ACLU-supported case Association for Molecular 
Pathology, et al. v. U.S. Patent and Trademark Office, et al. will help determine the 
future of gene patents in the United States. On March 29, 2010, United States District 
Court Judge Robert W. Sweet granted a summary judgment motion that invalidated 
patents on two genes linked to breast and ovarian cancer.
21  If upheld, this decision 




Restrictions on Gene Patenting in the United States 
 
Concerns about gene patenting have been voiced in the United States for years. In 
2007, a bill was introduced in Congress that would have essentially banned 
the patenting of DNA and DNA-related inventions. The Genomic Research and 
Accessibility Act (GRAA) would have radically altered United States patent law; GRAA 
would have banned patents on the human genome and all nucleotide sequences, including 
naturally occurring genes as well as synthetic DNA or RNA molecules.
23 GRAA was 
largely motivated by a perception that a proliferation of patents 
claiming human genes threatens to significantly impede biomedical research and block 
patient access to life-saving drugs and diagnostic testing services.
24 These fears have only 
increased in recent years.  In spite of those concerns, GRAA did not garner much support. 
 After its introduction and referral to subcommittees in early 2007, no movement has 
been reported, and the Act seems to have been abandoned.
25  
More recently, NIH-proposed guidelines recommend wide licensing of patented 
inventions to nonprofit researchers and public health agencies to promote patient health, 
emphasizing that exclusive licensing agreements have "'detrimental short-term and long-
term effects on both the quantity and quality of health care.'"
26 Following the filing of the 
present case, the Secretary’s Advisory Committee on Genetics, Health and 
Society (SACGHS) for the Department of Health and Human Services (HHS) has 
produced a report on gene patents titled Gene Patents and Licensing Practices and Their 7 
 
Impact on Patient Access to Genetic Tests.
27 The Committee proposes to exempt 
healthcare practitioners and researchers from infringement liability for gene patents. The 
recommendation, in its entirety:
28 
 
1. Supporting the Creation of Exemptions from Infringement Liability 
The Secretary of Health and Human Services should support and work 
with the Secretary of Commerce to promote the following statutory 
changes: 
          A. The creation of an exemption from liability for infringement of 
patent claims on genes for anyone making, using, ordering, offering for 
sale, or selling a test developed under the patent for patient care purposes. 
          B. The creation of an exemption from patent infringement liability 
for those who use patent-protected genes in the pursuit of research. 
 
With the report facing stiff opposition from the Biotechnology Industry 
Organization (BIO), legislative action may be a long time coming.
29 The BIO was joined 
by other prominent figures in its objection to the report’s recommendations.
30 Senator 
Birch Bayh, co-author of the Bayh-Dole Act, Dr. Brian Stanton, a member of the 
SACGHS Task Force on Intellectual Property and Access to Genetic Testing, and Dr. Jon 
Soderstrom, the Managing Director of the Office of Cooperative Research at Yale 
University, all appeared in support at the BIO press conference.  Former Indiana Senator 
Bayh maintained that the SACGHS recommendations would roll back the advances made 8 
 
under Bayh-Dole and "would have a disastrous impact on the American economy."
31 Dr. 
Jim Davis, Executive Vice President, General Counsel and Secretary of Human Genome 
Sciences, Inc., stated that gene patents are the backbone of biotech innovation, leading to 
both diagnostic and therapeutic products.
32 Without gene patents, therapeutic drugs 
tailored for specific individuals would be more expensive and less protected by the patent 
system.  Moreover, diagnostic testing such as that developed by Myriad would become 
open to the market at large. 
Currently, biotechnology companies are heavily invested in their gene patents.  
Personalized medicine, in which drugs are tailored for specific genes, uses the protected 
commercialization of those targeted genes.  Further, preventative care may depend on the 
development of more diagnostic tests such as the breast and ovarian cancer screenings at 
issue in this case. As one commentator states, if Myriad’s loses the case in further 
litigation “the legal foundation for much of the drug business in the United States and, 
thus, the whole world would crumble.”
33 Therefore, the biotechnology industry at large 
has a vested interest in any proposed legislation.  As do consumers awaiting new drug 
developments.  However, in spite of the variety of interests and the arguments made in 
favor of restricting gene patents, with such vocal dissent before proposed legislation even 
reaches Congress, it would be disingenuous to suggest that the issue will be resolved 
legislatively in the near future.  With economic and public health concerns at war with 
each other, gene patents will probably fall by the wayside in the legislative agenda.  In 
the meantime, it should be no surprise that researchers and opponents have already turned 
to litigation in an effort to eliminate gene patents. 9 
 
 
Does Gene Patenting Prevent Research? 
 
As reform efforts continue, the fear associated with gene patenting should be 
addressed.  Genes are an important component of disease research.  Horrific diseases 
such as cystic fibrosis and sickle cell anemia are linked to specific genes within the 
human body.
34  Newborns are tested for myriad genetic disorders simply as a matter of 
public health with fairly minimal costs.
35  However, the relationship between genes and 
most diseases is not nearly as straightforward.  Further research is required to understand 
gene interactions generally and drug targeting specifically. 
The plaintiffs in the Association for Molecular Pathology, et. al case claim that 
"[a]llowing patents on genetic material imposes real and severe limits on scientific 
research, learning, and the free flow of information."
36 This argument is central to the 
ACLU’s First Amendment concerns. In its brief, the ACLU argues that "the First 
Amendment limits the reach of intellectual property laws."
37 The ACLU labels six claims 
by which the defendants restrict the ability of researchers to observe and draw 
conclusions about patented genes, without confining that limitation to any particular 
methods of analyses. This prohibits the researchers from drawing any conclusions on 
patented BRCA genes, even if they used unpatented methods to study the genes.
38 For 
example, the ACLU cites Myriad's patent '999, which claims the act of looking at the 
patented BRCA1 gene. The ACLU also points to Myriad’s patent '001, which covers the 
comparison of a naturally occurring mutation with a patient's blood sample to confirm the 10 
 
presence of a gene mutation.  “The claim does not specify or claim any particular method 
of obtaining or comparing the sequences; it simply covers the act of looking at the two 
sequences and concluding they are the same or different," the ACLU states in its brief.
39 
Thus, the ACLU claims, researchers are prevented from conducting even the most basic 
studies of differences between the normal gene and the cancer-marker. 
The precise scope of Myriad’s patents, however, is unclear. A comprehensive 
search of legal databases conducted in 2007 attempted to identify every lawsuit that has 
ever been filed alleging infringement of a gene patent.
40  Many of the plaintiffs in the 
identified cases sued to restrict the infringer’s commercial use of a patented product 
rather than to limit the infringer’s research efforts. For instance, Myriad itself has filed 
suit in the past to enforce its BRCA patents.  In a widely publicized case, Myriad sued the 
University of Pennsylvania for infringing its patents relating to the BRCA breast cancer 
genes.
41 Although suits filed against a university appear to discourage research and 
diagnostics, in this case the university was engaged in substantial commercialization of 
the patented technology.
42 The university was conducting BRCA genetic testing services 
for a purported $1900 per test, in direct competition with Myriad’s test. Myriad has been 
heavily criticized for purportedly asserting its patents against universities, but this 
appears to be the only lawsuit brought by Myriad against a university.
43 
Other examples of litigation include suits brought by gene patent owners trying to 
ensure that biomedical research continues without impediment.  Specifically, a Ligand 
Pharmaceuticals Settlement Agreement explicitly granted two non-profit corporations 
named in the original suit a royalty-free, non-exclusive license to make and use the 11 
 
technology for the purposes of basic research. Apparently, Ligand was only interested in 
using its patent to block commercial infringement by a direct competitor, not to block 
basic research.
44 The original suit named both the La Jolla Cancer Research Foundation 
and SRI International as defendants. Ligand's complaint alleged that these institutions 
were directly involved in the creation of Selectra, a private company engaged in a drug 
discovery program that directly competed with Ligand's business and that allegedly 
infringed Ligand's patents.
45 The parties settled the case, with the defendants agreeing to 
shut down the spin-off company and cease commercial use of the patented technology.
46   
The number of infringement lawsuits being filed by gene patent owners has been 
declining.  Gene patent litigations peaked in 1997-1998, with a noticeable drop-off in 
recent years.
47 However, with increases in personalized medicine, including the 
diagnostic testing at issue in the current case, there may be a resurgence of gene patent 
litigation in the future.
48 Moreover, the number of cases does not accurately quantify the 
potential suppression of research.  In addition to lawsuits, Myriad has asserted its patent 
rights through cease-and-desist letters.  According to the original complaint, the company 
has enforced its BRCA1 and BRCA2 gene patent rights at least nine times, including 
against laboratories at Yale University.
49  
In the original complaint, one of the plaintiff’s major concerns is that Myriad can 
assert its patent rights at any given moment, so researchers are reluctant to conduct 
research that may subject them to a lawsuit.
50 The complaint states that there are 
members of the Association for Molecular Pathology, the American College of Medical 
Genetics, the American Society for Clinical Pathology and the College of American 12 
 
Pathologists who are “ready, willing, and able to engage in research and clinical practice 
involving the BRCA1 and BRCA2 genes if the patents are invalidated.”
51  
Furthermore, the chilling effect impacts more than direct research on BRCA1 and 
BRCA2.  Since the interaction of genes within the human cell is poorly understood at 
best, researchers refrain from studying genes that may interact with the patented genes.
52 
This is particularly concerning in light of recent advances in large-scale gene sequencing.  
Efforts to study how multiple genes can influence disease or cancer susceptibility are 
curtailed when some genes must be excluded due to gene patents.
53  
Additionally, gene patents are particularly powerful because they are impossible 
to design around.
54  Once a gene is patented, all non-licensed research related to that 
piece of DNA sequence ends until the expiration of the patent.
55 A researcher cannot 
create an alternative DNA sequence and still obtain meaningful clinical results.  Thus, 
drug research that interacts with the genes cannot occur outside the company that owns 
the patents. 
The number of genes thus restricted continues to increase. Between 1970 and 
1979, only 123 DNA-based patents were granted.
56 The number increased to 16,057 
between 1990 and 1999.
57  Since 2000, about 3,000 to 4,000 DNA-based patents have 
been granted each year.
58  In its report, the SACGHS noted that although researchers 
currently encounter only minor difficulties caused by human and gene patenting, “the 
complexity of the patent landscape is worrisome and may become ‘considerably more 
complex and burdensome over time.’”
59 As more genes are subject to patent protection, 
research options will contract.  This limits drug innovation to commercial companies.  13 
 
Whether directly enforced by lawsuits or cease-and-desist letters, or indirectly 
enforced by a chilling effect on research, the ACLU asserts that gene patents do not just 
have the potential to limit research, but that they do in fact limit research.  While the 
number of infringement lawsuits may be declining, there is no evidence that this has 




On May 12, 2009, the American Civil Liberties Union (ACLU) and the Public 
Patent Foundation (PUBPAT) filed a lawsuit against the U.S. Patent and Trademark 
Office (USPTO), Myriad Genetics (Myriad), and the University of Utah Research 
Foundation (UURF).  The suit challenged two patents on the human genes BRCA1 and 
BRCA2 that the USPTO had granted to Myriad and UURF.
60 The complaint, filed in the 
U.S. District Court for the Southern District of New York, charged that the patents 
covering isolated two human genes associated with breast and ovarian cancer are 
unconstitutional and invalid. The plaintiffs argued that patents on genes violate the First 
Amendment and statutory patent law because genes are "products of nature" and 
therefore cannot be patented.
61  Because of the complaint’s condemnation of the practice 
of gene patenting in general, the ACLU pointed out that the outcome in this case "could 
have far reaching effects beyond the patents on the BRCA genes."
62   
  Mutations in the BRCA genes cause most cases of hereditary breast and ovarian 
cancers.
63 Women with a familial history of breast or ovarian cancer are often encouraged 14 
 
to undergo genetic testing for BRCA gene mutations. The information provided allows 
earlier cancer detection and preventative care.
64 Myriad’s BRCA1 and BRCA2 gene 
patents give the company the exclusive right to perform diagnostic tests and to prevent 
researchers from studying the genes unless they have permission from Myriad.
65 Myriad 
controls the market entirely, preventing patients from obtaining a second opinion or 
alternative testing.
66 These specific concerns as well as objections to gene patenting in 
general are the driving force behind the lawsuit. 
The lawsuit was filed on behalf of researchers, genetic counselors, women 
patients, cancer survivors, breast cancer and women's health groups, and scientific 
associations representing 150,000 geneticists, pathologists, and laboratory 
professionals.
67 The complaint charged that the patents-in-suit stifle diagnostic testing 
and research that could lead to cures and limit women's options regarding their medical 
care. The ACLU claims that genes are products of nature and cannot be patented.
68 The 
ACLU also argues that patents on genes may hinder innovation because, under current 
law, Myriad and UURF would have the right to enforce patent protection against 
researchers studying or using these genes.
69 
Myriad has already faced resistance to the BRCA1 gene patent.
70  In May 2004, 
the European Patent Office revoked Myriad’s patent on the BRCA1 gene.
71 The French 
challenge to the Myriad patent was prompted by the possibility of incomplete 
diagnostics.  Specifically, Myriad forbade French doctors from undertaking BRCA1 
testing directly, instead requiring that the tests be sent to Myriad’s lab.
72 However, the 
sequencing technique used by Myriad Genetics failed to detect ten to twenty percent of 15 
 
BRCA1 mutations.
73 Similarly, a study published in the Journal of the American Medical 
Association concluded that there was a twelve percent rate of false negatives for 
Myriad’s genetic testing.
74 If diagnostic testing is conducted exclusively by one lab, that 
particular lab’s standards govern the entire process. Rather than running the risk of 
inaccurate diagnostic tests, the European Patent Office revoked the patent entirely.   
The ACLU has chosen the judicial system as a viable way to challenge gene 
patents. When the ACLU filed its Section 1983 action against the USPTO, Myriad, and 
the UURF, the complaint demanded that the BRCA gene patents be declared invalid as 
unpatentable under 35 USC § 101 "because human genes are products of nature, laws of 
nature and/or natural phenomena.” The complaint specifically claims that in granting the 
gene patents, the USPTO violated Article I, Section 8, Clause 8 and the First Amendment 
of the Constitution. 
To some commentators’ surprise, the lawsuit continued after Judge Robert W. 
Sweet reviewed the Motions to Dismiss submitted by the defendants in an attempt to 
block the judicial system from revoking human gene patents.
75 The defendants brought 
these motions under Federal Rules of Civil Procedure 12(b)(1) (for lack of subject matter 
jurisdiction), 12(b)(2) (for lack of personal jurisdiction), and 12(b)(6) (for failure to state 
a claim).
76  Specifically, the defendants argued that there is a specialized regulatory 
system in place to govern patents and to redress violations of the Patent Act.  Further, 
there is no statutory scheme providing a remedy for persons who complain about the 
constitutionality of patents issued by the USPTO and/or the policies and practices of the 
USPTO.
77 The defendants contended that there is simply no standing to sue and challenge 16 
 
the USPTO or the patents it grants since “it is well established that third parties do not 
have standing to challenge the USPTO’s issuance of a patent.”
78  The personal 
jurisdiction challenge raised by the defendants questioned whether the UURF Directors 
were subject to the New York District Court’s jurisdiction.
79 Finally, the defendants 
argued that the plaintiffs failed to sufficiently state a claim pursuant to Fed. R. Civ. P. 
12(b)(6).
80   
Judge Sweet denied the Motions to Dismiss on November 2, 2009, determining 
that under Fed. R. Civ. Pro. 12(b)(1) that the plaintiff's claims provided adequate grounds 
for subject matter jurisdiction. He found that “[t]he novel circumstances presented by this 
action against the USPTO, the absence of any remedy provided in the Patent Act, and the 
important constitutional rights the Plaintiffs seek to vindicate establish subject matter 
jurisdiction over the Plaintiffs’ claim against the USPTO.”
81 The court further ruled that 
the plaintiffs have standing to sue the Patent Office for "constitutional violations" despite 
the lack of statutory remedy.
82 
On the failure to state a claim basis for defendants' Motion to Dismiss, the district 
court found that the plaintiffs’ allegations of constitutional violations were sufficient, 
further holding that the complaint satisfied the stricter pleading requirements imposed by 
the Supreme Court in Ashcroft v. Iqbal.
83  The specific complaints meet the Iqbal 
requirements by alleging that the BRCA mutations are not inventions but "exist in 
nature," and that the correlation between the presence of these mutations and an increased 
risk of cancer are "nothing more than a naturally-occurring phenomenon" and therefore 
unpatentable.
84  Noting that the standard is a liberal one and that a complaint should be 17 
 
dismissed only if "it appears beyond doubt that the plaintiff can prove no set of facts in 
support of its claims that would entitle it to the relief it seeks," the court found that the 
pleadings were enough for the plaintiffs to withstand defendants' Motion to Dismiss.
 85 
After Judge Sweet denied the Motions to Dismiss, both plaintiffs and defendants 
filed motions requesting summary judgment.  Oral arguments were heard on February 02, 
2010.  Judge Sweet cited the complexities of the case and the importance of the suit when 
he announced that he would wait to make a decision on whether a case should be 
decided, go to trial, or be dismissed.
86  Thus, his decision to grant summary judgment to 
the plaintiffs on March 29, 2010 was surprising. 
 
Patentability of Genes 
 
In granting summary judgment, Judge Sweet held that Myriad's patents claiming 
"isolated DNA" do not qualify as patentable subject matter under 35 USC § 101.  This 
decision is a striking departure from previous patentability standards. 
Over two centuries ago, the framers of the U.S. Constitution codified incentives 
for technological innovation.
87 In return for a patent, the inventor must show that the 
invention satisfies a number of requirements, including a sufficient written description as 
well as utility, novelty, and nonobviousness.
88 Yet there are limits to what subject matter 
is considered patentable. For example, products of nature are not patentable.
89  One of the 
arguments brought forth by the ACLU is that genes are a product of nature, and therefore 
cannot be patented.  "Patenting human genes is like patenting E=mc
2, blood, or air,” 18 
 
argued ACLU attorney Chris Hansen.
90 Nevertheless, the scope of patentable subject 
matter is quite broad, encompassing “anything under the sun that is made by man.”
91 
DNA in the body is a product of nature and therefore not patentable.
92 Both 
plaintiffs and defendants recognized this basic point.
93  The patents at issue cover 
naturally occurring genes, but the defendants rely on the theory that the isolation of the 
BRCA genes — or the separation of the gene from the rest of the DNA— that is 
necessary to test and study genes makes them patentable.
94  “The novel compositions and 
methods resulted from the identification and isolation of two genes,”
95 rather than from 
DNA that exists in nature. 
The case for patenting modified genes is fairly direct.  In 1980, the United States 
Supreme Court's decision in Diamond v. Chakrabarty allowed the patenting of a living 
organism.
96 The Court determined that a living organism could be viewed as a 
“manufacture, or [a] composition of matter,” falling within two categories 
of patentable subject matter.
97  Moreover, congressional intent suggested that patentable 
subject matter should be broadly construed under Section 101 of the Patent 
Act.
98 Therefore, the Court concluded that a genetically modified organism 
is patentable subject matter because it is “a product of human ingenuity,” not a “hitherto 
unknown natural phenomenon.”
99 The Court in Chakrabarty found that 
the patentability of a living organism depended on whether the living thing was modified 
by a human, and thus refused to take an ethical stand on the issue.
100  Following this line 
of logic, although genes are regarded as natural parts of an organism, they 19 
 
are patentable subject matter under Section 101 as long as the genes sought to 
be patented are modified by a researcher. 
However, Chakrabarty alone does not justify the patenting of a naturally 
occurring gene. Chakrabarty explained that a claimed product must have “markedly 
different characteristics” from the natural phenomenon and that the use of the claimed 
product must be a result of the inventor’s effort, not “nature’s handiwork.”
101  The 
rationale for patenting a gene with its sequence unmodified is based on the 1970 In re 
Bergstrom decision, in which the Court of Customs and Patent Appeals held that a 
purified form of a compound was patentable even though its impure form was known to 
the public.
102 A compound merely discovered in nature would not be patentable, but 
because the pure form of the compound does not exist in nature, the purified compound is 
patentable subject matter.
103 Moreover, patentability is not destroyed even if the pure 
form of the compound has the same function as the compound found in nature.
104 
Although genes exist in nature as part of DNA, they do not exist in their pure form.  An 
isolated and identified gene would then be patentable under Section 101 without its 
sequence being modified by a researcher.  The conclusion that an isolated and purified 
gene is patentable was accepted by the Federal Circuit.
105 
According to the defendants, under In re Bergstrom, Myriad’s isolation and 
purification of the gene qualify the gene for patentability. The USPTO has considered 
this argument before and agrees with the defendants.  Following criticism that the 
USPTO was too liberal in approving gene patents,
106 internal review led to the conclusion 
that the agency was bound by policy and case law to reject arguments that genes were 20 
 
products of nature and thus unpatentable.
107 In granting summary judgment, Judge 
Sweets disagreed with the USPTO and moved away from Federal Circuit precedent. 
 
Summary Judgment Decision 
 
It is rare for a plaintiff to succeed in a summary judgment motion because the 
plaintiff bears the burden of proof.
108 In granting summary judgment, Judge Sweet 
determined that there were no issues of material fact to be decided. Judge Sweet used a 
straightforward application of patent law to invalidate the patents. 
The decision divided the patent claims into two groups: patents claiming gene sequences 
that had been isolated from DNA and patents claiming methods for analyzing genes in 
order to identify breast or ovarian cancer markers. Both sets of claims were rejected 
under Section 101 of the Patent Act. 
Isolated Genes 
Judge Sweet held that isolated genes are insufficiently different from naturally 
occurring DNA and thus are ineligible for patent protection. In so holding, the court 
emphasized the separation between patentable subject matter and other sections of the 
Patent Act.
109  Just because a discovery is new or useful doesn’t make it patentable. Cases 
cited by Myriad were distinguished as addressing novelty and obviousness concerns, not 
the question of patentable subject matter.
110  There is a separate determination for 
patentable subject matter; in this case, whether the genes are products of nature or 21 
 
inventions.  In Chakrabarty, the court specifically stated that “the laws of nature, physical 
phenomena, and abstract ideas have been held not patentable.”
111   
Myriad asserted that the isolated genes were not simply products of nature, 
arguing that the isolated genes were “substantially separated from other cellular 
components which naturally accompany a native human sequence [such as] human 
genome sequences and proteins.”
112 The defendants argued that the purification of 
naturally occurring BRCA genes renders them patentable, especially in light of that 
‘substantial separation.’
113  
Tracing a line of cases from the 1874 decision in American Wood-Paper Co. v. 
Fibre Disintegrating Co. to Chakrabarty in 1980, the court concluded that “purification 
of a product of nature, without more, cannot transform it into patentable subject matter. 
Rather, the purified product must possess ‘markedly different characteristics’ in order to 
satisfy the requirements of §101.”
114  The question is whether the BRCA genes meet this 
standard. 
In the decision, the court found that Myriad’s isolated genes failed the test and 
were nothing more than products of nature.  The function of a gene does not vary from its 
function in vivo when it is isolated in a laboratory setting. Instead, Judge Sweet 
determined that “DNA represents the physical embodiment of biological information, 
distinct in its essential characteristics from any other chemical found in nature. It is 
concluded that DNA’s existence in an ‘isolated’ form alters neither this fundamental 
quality as it exists in the body nor the information it encodes.”
115 The critical aspect of 
DNA is that it carries information; it does not operate simply as a chemical.  Thus, the 22 
 
isolated BRCA genes fail to demonstrate markedly different characteristics from BRCA 
genes in the human body.  
The court’s focus on genes as something more than merely chemicals is a 
substantial departure from precedent.
116  With this decision, genes now fall outside of the 
In re Bergstrom holding that simply requires the purification of naturally occurring 
chemicals in order for those chemicals to be patentable.  This distinction demolishes the 
foundation of gene patenting. Any purified or isolated version of a naturally occurring 
gene would fail the test for patentability. 
 
Methods for Gene Analysis 
In the second part of its analysis, the court applied the “machine or 
transformation” test from the Federal Circuit’s decision in In re Bilski to the method 
claims in the patents.
117 In applying this test, Judge Sweet held that the patent claims 
were not linked to any machine, nor was there any tangible transformation.  There was no 
restriction on the methods used to compare the genes and no further actions described 
beyond analyzing the genes.  The method claims that required comparison between DNA 
sequences were abstract mental processes and therefore unpatentable subject matter.
118  
Even if the patent claims had explained how to isolate and sequence the DNA, 
this would merely be information gathering and would not have saved the patent from 
being rejected.
119  In spite of the physical transformations required to isolate DNA, Judge 
Sweet determined that the claims would “would still fail the ‘machine or transformation’ 
test under § 101 for subject matter patentability” under Bilski.
120 23 
 
Although raised by the ACLU and cited in Judge Sweet’s decision on the Motions 
to Dismiss, the constitutional arguments were not addressed in the decision granting 
summary judgment. Judge Sweet applied the doctrine of constitutional avoidance to 
refrain from unnecessarily ruling on constitutional questions.
121 Since the patents were 
invalidated on other grounds and the plaintiffs gained the requested relief, the 
constitutional claims against the USPTO were dismissed without prejudice.
122 
The summary judgment decision invalidated claims for both isolated genes and 
methods for gene analysis, leaving gene patenting in a very precarious position in the 
New York District Court. 
 
Implications of the Decision 
 
  The immediate effect of the decision should not be overstated.  Myriad will 
certainly appeal the summary judgment to the Federal Circuit.
123 Judge Sweet’s decision 
will only apply to the patents at issue in the present case and will not be binding on any 
other court.
124 Thus the vast majority of the pharmaceutical industry can continue 
developing drugs based on gene patents without immediate fear that their work will be 
unprotected by United States law.  However, the decision does present an excellent test 
case for the Federal Circuit and perhaps the Supreme Court to address gene patentability.  
Should the Federal Circuit uphold the ruling, it will be binding on all federal courts 
except the Supreme Court. 
125 A ruling that upheld Judge Sweet’s decision would force 
changes in the biotechnology industry. 24 
 
Judge Sweet’s ruling has an effect beyond its legal decision.  As mentioned 
above, attempts to restrict gene patenting through the legislature have been unsuccessful. 
Thus, any court moving on this issue can expect media attention. Gene patenting was at 
the heart of this case, and the decision unequivocally invalidated patents on naturally 
occurring genes.  The simplicity of this fact is evidenced by the articles that shortly 
followed the summary judgment decision. “Judge Invalidates Human Gene Patent,” 
“Judge Nullifies Gene Patents,” and “The End of Gene Patenting?” are just a few of the 
articles and blog postings published in the wake of the decision.
126 
Additionally, the plaintiffs chose an excellent case from a policy perspective. 
Many women are at risk for breast and ovarian cancer and see genetic testing as one of 
the few preventative measures available.
127  The plaintiffs are universities, professional 
organizations and cancer patients who could not afford to pay Myriad’s monopoly price 
on diagnostics: quintessentially sympathetic figures.   Should the Federal Circuit overturn 
the decision, it will be seen not just as a legal or scientific matter, but also as a social 
concern.  The failure of the courts to protect the interests of sympathetic plaintiffs may 
spur popular support for legislative reform in a way that other patent cases would not.   
On the research front, this decision may shift the biotechnology industry away 
from gene isolation.  Bryan Roberts, a prominent Silicon Valley venture capitalist, stated 
that “[t]he government is going to become the funder for content discovery because it’s 
going to be very hard to justify it outside of academia.”
128 However, the decision could 
also spur the development of synthetic genes for testing and shift the focus away from 
naturally occurring genes.
129 This level of creativity is particularly important during a 25 
 
time when “medicine [is] becoming more personalized, with genetic tests used not only 
to diagnose diseases but to determine which medicine [is] best for which patient.”
130  
A federal court decision that invalidates specific gene patents on Section 101 
grounds calls into question all gene patents.  If DNA is a product of nature and an 
isolated gene does not possess markedly different characteristics, then the isolated gene is 
not patentable according to Judge Sweet’s analysis.  Even if the Federal Circuit overturns 
the decision, the outcome of the case has placed gene patents under far more public 
scrutiny than has existed in the past. 
As an industry, biotech companies must decide how to proceed with their 
business models.  If the Biotechnology Industry Organization is correct and this 
fundamentally changes how pharmaceutical research is conducted within the United 
States, companies cannot be complacent.  While the Federal Court may overturn the 
decision entirely or (more likely) simply alter the scope of gene patents, companies 
cannot afford to depend on this outcome. 
Certainly, research allocation must adjust if gene research protections change.  
Even if the courts strike down gene patents generally, there are ways for companies to 
pursue innovation while maintaining patent protections.  As mentioned above, synthetic 
genes are still patentable under Judge Sweet’s decision, so would still be protected by 
patent laws.  But even natural genes are not entirely outside the scope of protection 
during drug development. For instance, the application of a gene function, as long as the 
application is a non-obvious application of knowledge of a gene function, may be 
patentable.
131 This would hold true even if gene patents are eliminated by the courts or 26 
 
legislatively.  The industry is working through organizations such as BIO to prevent 
changes to the laws, but individual companies should protect their own investments by 
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